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 Obesity is a major public health problem that contrib-
utes to the development of type 2 diabetes and cardiovas-
cular disease ( 1 ). Excessive lipid accumulation in adipose 
tissue is a key pathological driver of obesity, and is mani-
fested by an increase in the number (hyperplasia) and size 
(hypertrophy) of adipocytes. Differentiation of preadipo-
cytes to mature adipocytes (adipogenesis) is an integral 
mediator of this process, and is under the control of a 
transcription factor network that regulates lipid biosynthe-
sis and metabolism ( 2 ). Most notably, PPAR-  , CCAAT/
enhancer-binding protein (C/EBP)  , and sterol regulatory-
element-binding protein (SREBP)1c are central mediators 
of this process through the regulation of LPL, acetyl-CoA 
carboxylase 1 (ACC1), and FAS expression ( 2, 3 ). Sustained 
activation of this process, however, is a key pathological 
driver of obesity that results in adipocyte dysfunction, glu-
cose intolerance, and ultimately the development of insu-
lin resistance and type 2 diabetes ( 4, 5 ). Consequently, an 
improved understanding of the key pathways that regulate 
adipogenesis and adipocyte function offers enormous po-
tential to facilitate the development of novel therapeutic 
strategies that mitigate the development and progression 
of obesity-associated metabolic diseases. 
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 Oil Red O staining 
 On day 8, 3T3-L1 cells were washed in PBS, fi xed in 4% (w/v) 
formaldehyde for 30 min, and then washed twice in PBS. The 
cells were stained with 0.2% Oil Red O in 60% 2-propanol for 
15 min and washed twice with PBS, as described ( 17 ). Images 
were obtained with a bright fi eld microscope equipped with an 
image recorder under a 20× lens. In order to quantify lipid ac-
cumulation, the Oil Red O was eluted with 100% isopropanol for 
5 min, and then quantifi ed by spectrophotometry at an absor-
bance of 490 nm (BioTek Instruments). 
 Animals 
 All experiments were performed in adult male mice on a 
C57BL/6 background. WT C57BL/6 mice were purchased from 
Jackson Laboratory (Bar Harbor, ME). A colony of mice with tar-
geted disruption of  Ephx2 ( Ephx2   /   ) was rederived and back-
crossed onto a C57BL/6 genetic background for more than 10 
generations and genotyped by PCR, as described previously ( 18, 
19 ). All mice had free access to food and water, and were housed 
in controlled conditions for temperature and humidity using a 
12 h light-dark cycle. All experiments were completed in accor-
dance with the US National Institutes of Health (NIH) Guide for 
the Care and Use of Laboratory Animals, and were approved by 
the Institutional Animal Care and Use Committee. 
 Induction of obesity in mice 
 In experiment A, WT C57BL/6 mice (age 8–10 weeks) re-
ceived a low-fat control diet [D12450B (10% kcal fat)], a high-fat 
“Western” diet [D12079B (41% kcal fat)], or a “very” HFD 
[VHFD, D12492 (60% kcal fat)] for 4 weeks (n = 6/group). Each 
diet is commercially available (Research Diets, New Brunswick, 
NJ), and is not enriched with arachidonic acid (<1 g per kg in 
each diet). In experiment B, WT mice (age 8–10 weeks) were fed 
the VHFD for 4 weeks, and received EET-A continuously in the 
drinking water (100 mg/l), or vehicle control (water), over the 
course of the experiment (n = 4–8/group). In experiment C, WT 
mice (age 8–10 weeks) were fed the VHFD for 2 weeks, and re-
ceived either NUDSA (15 mg·kg   1 ·day   1 ) or vehicle (10% etha-
nol) once daily via intraperitoneal injection over the course of 
the experiment (n = 6/group). In experiment D,  Ephx2   /   and 
corresponding WT control mice (age 16–20 weeks) were fed the 
“Western” diet (n = 11–14/group) for either 4 or 8 weeks. 
 In each experiment, body weight and food consumption were 
monitored weekly. Mice were euthanized by CO 2 inhalation, and 
epididymal white adipose tissue (eWAT) was harvested and 
weighed; one part of the tissue was snap-frozen in liquid nitrogen 
and stored at   80°C, while the remainder was fi xed in 4% para-
formaldehyde and embedded in paraffi n for histological analysis. 
 Eicosanoid extraction and measurements 
 Eicosanoid metabolites were extracted from 3T3-L1 culture 
medium and mice eWAT by solid-phase extraction and quanti-
fi ed by HPLC-MS/MS, as described ( 20 ). Briefl y, culture me-
dium (3 ml) was spiked with internal standard [3 ng PGE 2 -d 4 , 
10,11-DiHN, and 10(11)-EpHep (Cayman)], and then acidifi ed 
with 330   l of 1% acetic acid in 50% methanol. Frozen eWAT 
(50 mg) was homogenized in 400   l ice-cold methanol with 0.1% 
acetic acid and internal standard for 10 min, centrifuged at 
10,000 rpm for 10 min at 4°C, and the pellets were re-extracted 
with 100   l of ice-cold methanol with 0.1% of acetic acid. The 
supernatants were combined with 2 ml of water and shaken. Fol-
lowing serial passage through HyperSep Retain SPE columns 
(Thermo Scientifi c, Bellefonte, PA), the columns were washed 
and then eluted with 0.5 ml of methanol and 1 ml of ethyl acetate 
 In addition to a well-established role in xenobiotic me-
tabolism, cytochromes P450 (CYPs) metabolize essential 
fatty acids to bioactive eicosanoids in various cell types. 
Most notably, arachidonic acid is metabolized by CYP2J 
and CYP2C epoxygenases to epoxyeicosatrienoic acids 
(EETs), which are rapidly hydrolyzed by soluble epoxide 
hydrolase (sEH,  Ephx2 ) ( 6 ). CYP-derived EETs are key 
regulators of a myriad of biological processes in the car-
diovascular system, including vascular tone and infl am-
mation ( 7, 8 ). It also has been reported that EETs elicit 
protective effects in obesity-associated metabolic disease 
( 9–12 ). However, the impact of adipogenesis and obesity 
on EET biosynthesis in adipose tissue and the functional 
role of EETs in the regulation of adipogenesis and the 
pathogenesis of obesity remains poorly understood. 
 Consequently, using established in vitro (differentiated 
3T3-L1 cells) and in vivo [high-fat diet (HFD)-fed mice] 
models, we investigated:  a ) the impact of adipogenesis and 
obesity on the bioavailability of adipose-derived EETs; and 
 b ) the functional effects of EETs on adipogenesis and obe-
sity, and their downstream pathological consequences . 
 MATERIALS AND METHODS 
 Reagents 
 Reagents were obtained from Sigma-Aldrich (St. Louis, MO) 
unless otherwise indicated. The stable EET analog 14,15-epoxye-
icosa-8(Z)-enoic acid (14,15-EE-8(Z)-E) and CYP epoxygenase 
inhibitor N-(methylsulfonyl)-2-(2-propynyloxy)-benzenehexan-
amide (MS-PPOH) were purchased from Cayman Chemical 
(Ann Arbor, MI). The stable EET analogs (S)-2-(11-(nonyloxy) 
undec-8(Z)-enamido)succinic acid (NUDSA) and (S)-2-(13-(3-
butylureido) tridec-8(Z)-enamido)succinic acid (EET-A, sodium 
salt) were synthesized by Dr. John Falck (University of Texas 
Southwestern, TX) ( 13, 14 ). 
 Peptide-based antibodies that cross-react with murine Cyp2c55 
(anti-Cyp2c55 #1545) and Cyp2j9 (anti-Cyp2j9pep2), and recom-
binant Cyp2c55 and Cyp2j9 proteins, were provided by Dr. Darryl 
Zeldin (National Institute of Environmental Health Sciences, 
Research Triangle Park, NC ) ( 15, 16 ). Antibodies against murine 
sEH (sc22344) and GAPDH (#2118) were purchased from Santa 
Cruz Biotechnology (Santa Cruz, CA) and Cell Signaling Tech-
nology (Danvers, MA), respectively. 
 3T3-L1 cell culture and differentiation 
 Murine 3T3-L1 preadipocytes were obtained from ATCC 
(Manassas, VA). Preadipocytes were cultured to confl uence in DMEM 
with 10% newborn calf serum and 1% penicillin-streptomycin at 
37°C with 5% CO 2 , and then chemically differentiated into 
mature adipocytes over 8 days [days 0–2: 10% FBS DMEM with 
0.5 mM 3-isobutyl-1-methyl-2,6(1H,3H)-purinedione, 10   g/ml 
insulin, and 1   M dexamethasone; days 2–4: 10% FBS DMEM 
with 10   g/ml insulin; days 4–8: 10% FBS DMEM only], as 
described ( 17 ). 
 In the eicosanoid profi ling experiments, culture media were 
collected every 2 days and cells were collected on day 0 and day 8. 
In the treatment experiments, cells were differentiated for 8 days 
and concurrently treated with MS-PPOH (1, 5, 10, and 20   M), 
NUDSA (1, 5, and 10   M), 14,15-EE-8-ZE (0.1, 0.5, and 1.0   M), 
or vehicle control. Cells and media were harvested and stored at 
  80°C for RNA/protein isolation and eicosanoid extraction. 
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at 4°C overnight, washed, and then incubated with the appro-
priate horseradish peroxidase-conjugated secondary antibody 
(Santa Cruz Biotechnology). Immunoreactive bands were de-
tected by chemiluminescence using the ECL Western blotting 
substrate (Thermo Scientifi c). The density of the immunoreac-
tive bands was analyzed using ImageJ software (NIH). 
 CYP epoxygenase and sEH activity assay 
 In order to quantify CYP epoxygenase metabolic activity, 3T3-
L1 preadipocytes and mature adipocytes were seeded in 12-well 
plates, supplemented with 1 ml of medium containing 10   M 
arachidonic acid for 30 min (n = 4/group), and then EET and 
DHET concentrations in the medium were quantifi ed by HPLC-
MS/MS. Sum EET+DHET and sum EET concentrations were 
calculated and normalized to cell density. In order to quantify 
cellular sEH metabolic activity, 25 ng 14,15-EET was incubated 
with 1   g total cell lysate from 3T3-L1 preadipocytes or mature 
adipocytes in a 0.1 ml volume of PBS plus 0.1 mg/ml BSA for 
10 min at 37°C, as described ( 25 ). The reactions were stopped 
with 1 ml of ice-cold ethyl acetate, spiked with internal standard, 
and then evaporated to dryness under nitrogen gas. The residue 
was reconstituted in 30% ethanol, and EET and DHET concen-
trations were quantifi ed by HPLC-MS/MS. The 14,15-EET:14,15-
DHET ratio was calculated as a biomarker of sEH metabolic 
activity ( 26 ). 
 eWAT histology 
 Paraffi n-embedded eWAT tissue underwent serial interrupted 
sectioning (5   m sections, 100   m apart), and then were stained 
with hematoxylin and eosin (H&E) and scanned into digital im-
ages (ScanScope CS; Aperio, Vista, CA). The average adipocyte 
size per 10× fi eld was quantifi ed using ImageJ software (NIH) 
and the MRI adipocyte tool, as described ( 27 ). An average value 
across nine nonoverlapping fi elds (three fi elds/section × three 
sections/mouse) was calculated for each mouse. 
 Body composition and metabolic measurements 
 Body composition was measured in live mice without anesthe-
sia by quantitative magnetic resonance using an EchoMRI-100 
whole body composition analyzer (EchoMRI, Houston, TX), as 
described ( 28 ). Fat and lean mass were quantifi ed at baseline, 
week 2 and week 4, and expressed as a percentage of total body 
weight. At week 3, oxygen consumption (VO 2 ) and carbon diox-
ide production (VCO 2 ) were quantifi ed by indirect calorimetry 
in unrestrained individually housed mice using a TSE LabMaster 
system (TSE Systems, Chesterfi eld, MO), which also quantifi es 
food and water consumption ( 28 ). Measurements were obtained 
in 27 min intervals over 24 h, normalized to total body weight, 
and averaged. The respiratory exchange ratio (RER = VCO 2 /
VO 2 ) and metabolic rate [= (3.815 + 1.232 × RER) × VO 2 ] were 
calculated. 
 Glucose tolerance test 
 Mice were fasted 6 h, and then dosed with 20% D-glucose by 
intraperitoneal injection (week 4: 2 mg/g body weight; week 8: 
1 mg/g body weight). Whole blood glucose concentrations were 
measured before and 20, 30, 60, 90, and 120 min following dos-
ing using the Accu-Chek Aviva Plus glucometer (Roche Diagnos-
tics GmbH, Mannheim, Germany), as described ( 29 ). Due to 
progressive glucose intolerance and the upper limit of detection 
of the glucometer (600 mg/dl), a lower glucose dose was used at 
8 weeks. The area under the glucose concentration-time curve 
(glucose AUC 0–120min ) was calculated using the trapezoidal 
method. 
into glass tubes with 10   l of trapping solution (30% glycerol in 
methanol). The eluates were dried under N 2 and reconstituted 
in 50   l of 30% ethanol. 
 Online LC of extracted samples was performed with an Agi-
lent 1200 series capillary HPLC (Agilent Technologies, Santa 
Clara, CA). Separations were achieved using a Halo C18 column 
(2.7   m, 100 × 2.1 mm; MAC-MOD Analytical, Chadds Ford, PA), 
which was held at 50°C and a fl ow rate of 400   l/min. Mobile 
phase A was 0.1% acetic acid in 85:15 water:acetonitrile. Mobile 
phase B was 0.1% acetic acid in acetonitrile. Gradient elution was 
used and the mobile phase was varied as follows: 20% B at 0 min, 
ramp from 0 to 5 min to 40% B, ramp from 5 to 7 min to 55% B, 
ramp from 7 to 13 min to 64% B. From 13 to 19 min the column 
was fl ushed with 100% B at a fl ow rate of 550   l/min before be-
ing returned to starting conditions and equilibrated for 6 min. 
Samples were solvated in 50   l of 30% ethanol and injected in 
triplicate at 10   l per injection. 
 Electrospray ionization MS/MS was used for detection. Analy-
ses were performed on an MDS Sciex API 3000 equipped with a 
TurboIonSpray source (Applied Biosystems, Foster City, CA). 
Turbo desolvation gas was heated to 425°C at a fl ow rate of 6 l/
min. All analytes were monitored simultaneously in a scheduled 
multiple reaction monitoring experiment as negative ions at 
parent ion-product ion mass/charge ratio pairs and retention 
times. The relative response ratios of each analyte were used to 
calculate concentrations, while correcting for surrogate losses 
via quantifi cation relative to internal standards. Cell medium 
concentrations were normalized to cell density. Adipose tissue 
concentrations were normalized to tissue weight. The sum con-
centration of EETs (14,15-EET, 11,12-EET, and 8,9-EET), dihy-
droxyeicosatrienoic acids (DHETs) (14,15-DHET, 11,12-DHET, 
8,9-DHET, and 5,6-DHET), and total EETs+DHETs were cal-
culated as biomarkers CYP epoxygenase metabolic function 
( 19, 21 ). 
 RNA isolation and quantitative RT-PCR 
 Total 3T3-L1 cellular eWAT and brown adipose tissue 
(BAT) RNA were isolated using the RNeasy Miniprep kit (Qiagen, 
Valencia, CA). Total RNA (2   g) was reverse transcribed to cDNA, 
as described ( 19 ). Expression of murine  Cyp2j5 (Mm00487292_
m1),  Cyp2j9 (Mm00466423_m1),  Cyp2c29 (Mm00725580_s1), 
 Cyp2c44 (Mm01197184_m1),  Cyp2c55  (Mm00472168_m1), 
 Ephx2 (Mm01313813_m1),  Ephx3 (Mm01345663_m1),  PPAR  
(Mm01184322_m1),  C/EBP  (Mm00514283_s1),  SREBP1c 
(Mm00550338_m1),  LPL (Mm00434764_m1), fatty acid binding 
protein 4 ( Fabp4 ) (Mm00445878_m1),  ACC1 (Mm01304257_m1), 
 FAS (Mm00662319_m1),  Tnfa (Mm00443258_m1), uncoupling 
protein 1 ( UCP1 ) (Mm01244861_m1),  Actb (Mm00607939_s1), 
and  GAPDH (Mm99999915_g1) were quantifi ed using TaqMan® 
Assays on Demand (Applied Biosystems). The effi ciency of each 
quantitative RT-PCR (qRT-PCR) probe for the eicosanoid me-
tabolism genes was previously calculated over a range of cDNA 
amounts (1–100 ng), and was equivalent for all probes ( 22 ). 
Gene expression was normalized to GAPDH or   -actin and ex-
pressed relative to control using the 2     Ct method ( 23 ). 
 Immunoblotting 
 Total 3T3-L1 cell lysates were prepared and the protein 
concentration was quantifi ed, as described ( 24 ). Total protein 
(30   g) was resolved and separated by 10% NuPAGE Bis-Tris 
gels, and then transferred to nitrocellulose membranes (Invitrogen). 
Membranes were blocked in 5% nonfat milk in TBS for 2 h at 
room temperature, incubated with anti-Cyp2j9 (1:1,000), anti-
Cyp2c55 (1:1,000), anti-sEH (1:1,000), or anti-GAPDH (1:4,000) 
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 TABLE 1. Metabolite set enrichment analysis in 3T3-L1 preadipocytes and differentiated adipocytes 
Pathways (8) Metabolites (33) Total Q Statistic Raw  P Value Holm  P Value a FDR a 
CYP epoxygenase-derived 
  arachidonic acid metabolites
8,9-EET, 11,12-EET, 14,15-EET, 5,6-DHET, 
  8,9-DHET, 11,12-DHET, 14,15-DHET
7 86.60 1.69E-16 1.35E-15 1.35E-15
CYP epoxygenase-derived 
  linoleic acid metabolites
9,10-EpOME, 12,13-EpOME, 
  9,10-DiHOME, 12,13-DiHOME
4 85.07 3.61E-15 2.53E-14 1.47E-14
Lipoxygenase-derived 
  arachidonic acid metabolites
15-HETE, 12-HETE, 11-HETE, 
  8-HETE, 5-HETE
5 84.86 7.39E-14 4.43E-13 1.97E-13
Lipoxygenase-derived 
  linoleic acid metabolites
9,12,13-TriHOME, 9,10,13-TriHOME, 
  13-HODE, 9-HODE
4 37.21 1.50E-05 7.49E-05 2.99E-05
CYP hydroxylase-derived 
  arachidonic acid metabolites
19-HETE, 20-HETE 2 41.72 5.82E-05 2.33E-04 9.31E-05
Cyclooxygenase-derived 
  arachidonic acid metabolites
6-keto-PGF1  , TxB2, PGF2  , PGD2, 
  PGE2, 8-iso-PGF2  , PGB2
7 21.53 5.46E-04 1.64E-03 7.28E-04
CYP epoxygenase-derived 
  docosahexaenoic acid metabolites
19,20-DiHDPA, 19,20-EpDPE 2 14.93 0.029 0.058 0.033
CYP epoxygenase-derived 
  eicosapentaenoic acid metabolites
17,18-DiHETE, 17,18-EpETE 2 1.94 0.447 0.447 0.447
DiHDPA, dihydroxydocosapentaenoic acid; DiHETE, dihydroxyeicosatetraenoic acid; DiHOME, dihydroxyoctadecenoic acid; EpDPE, 
epoxydocosapentaenoic acid; EpETE, epoxyeicosatetraenoic acid; EpOME, epoxyoctadecenoic acid; PG, prostaglandin; TriHOME, 
trihydroxyoctadecenoic acid; Tx, thromboxane.
 a The pathways (rank-ordered) were considered signifi cantly enriched when the Holm  P < 6.25E-03 and FDR <5%.
separation of the global eicosanoid profi le across preadi-
pocytes and differentiated adipocytes ( Fig. 1C ). Notably, the 
CYP epoxygenase-derived arachidonic acid pathway was 
the most signifi cantly changed metabolite set during adipo-
cyte differentiation ( Table 1 ). The sum EET, sum DHET, and 
sum EET+DHET concentrations were signifi cantly reduced 
in 3T3-L1 mature adipocytes compared with preadipocytes 
( Fig. 1D ). This was apparent after 2 days and sustained 
throughout the entire differentiation period ( Fig. 1E–G ). 
 We subsequently assessed expression of key CYP epoxygen-
ases ( Cyp2j5 ,  Cyp2j9 ,  Cyp2c29 ,  Cyp2c44 , and  Cyp2c55 ) and ep-
oxide hydrolases ( Ephx2 and  Ephx3 ) ( Fig. 2A ). Cyp2j9 and 
Cyp2c55 protein levels were reduced and sEH protein was 
increased in mature adipocytes compared with preadipocytes 
( Fig. 2B–D ). Consistent with the expression data, the capacity 
to generate EETs and DHETs (CYP epoxygenase metabolic 
activity) was signifi cantly lower ( Fig. 2E, F ) and the capacity 
to hydrolyze 14,15-EET to 14,15-DHET (sEH metabolic activ-
ity) was signifi cantly higher ( Fig. 2G ) in mature adipocytes. 
These fi ndings indicate that induction of adipogenesis dys-
regulates the CYP epoxygenase pathway and suppresses the 
bioavailability of EETs in adipocytes. 
 Diet-induced obesity suppresses CYP epoxygenase-
derived EETs in adipose tissue in vivo 
 Mice fed two distinct HFDs each exhibited a signifi cant 
increase in total body weight gain ( Fig. 3A ) and eWAT 
weight ( Fig. 3B ) at 4 weeks. High-fat feeding significantly 
reduced EET and DHET levels in eWAT, in both models, 
compared with controls ( Fig. 3C, D ). Furthermore, eWAT 
EET levels inversely correlated with body weight gain 
( r =   0.633,  P = 0.005), adipose tissue weight ( Fig. 3E ), key 
biomarkers of adipogenesis [SREBP1c ( r =   0.733, 
 P = 0.001), C/EBP  ( r =   0.506,  P = 0.032), and PPAR  
( r =   0.485,  P = 0.041) mRNA levels in eWAT], and activa-
tion of the infl ammatory response in eWAT ( Fig. 3F ). 
Taken together, these results are consistent with our in 
vitro experiments and indicate that induction of adipose 
tissue expansion suppresses EET levels in eWAT. 
 Metabolomic analysis 
 A total of 33 distinct eicosanoid metabolites were quantifi able 
by HPLC-MS/MS in the 3T3-L1 cell culture media. A principal 
components analysis (PCA) was employed in the MetaboAnalyst 
2.0 web portal ( 30 ) to identify whether changes in the global 
eicosanoid profi le occurred during adipocyte differentiation 
(n = 4/time-point). The PCA results were displayed as score plots 
to visualize sample clustering and to indicate sample differences 
across the differentiation time-course. The relative impact of adi-
pocyte differentiation on eight self-defi ned eicosanoid metabolic 
pathways ( Table 1 ) was evaluated by quantitative enrichment 
analysis, which is based on the global test algorithm and uses a 
generalized linear model to estimate a Q-statistic for each me-
tabolite set. Pathways were considered signifi cantly enriched 
when  P < 0.00625 (= 0.05/8), and the corresponding false discov-
ery rate (FDR) was <5%. 
 Statistical analysis 
 All data were expressed as mean ± SEM. A one-way ANOVA 
was employed to analyze the differences across treatment groups 
followed by a post hoc Dunnett’s test to evaluate whether treat-
ment differences existed relative to the control group. A post hoc 
Wilcoxon rank-sum test was used for data that were not normally 
distributed. Differences in the glucose concentration-time pro-
fi le were determined using general linear model repeated-
measures ANOVA, and a post hoc Scheffe’s test. Correlations 
were evaluated using the Spearman rank correlation where in-
dicated. Statistical analysis was performed using SAS-JMP 6.0 or 
SAS 9.2 software (SAS Institute, Cary, NC), and  P < 0.05 was 
considered signifi cant. 
 RESULTS 
 Adipocyte differentiation suppresses CYP 
epoxygenase-derived EETs in vitro 
 We fi rst investigated the effect of adipocyte differentiation 
over time on the global eicosanoid profi le in 3T3-L1 adipo-
cytes. Oil Red O staining ( Fig. 1A ) and  Fabp4 mRNA levels 
( Fig. 1B ) confi rmed the differentiation of preadipocytes into 
mature adipocytes. The PCA analysis demonstrated a clear 
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termine whether the early phase adipocyte differentiation 
was most sensitive to the anti-adipogenic effects of EET 
analog administration. Treatment with 14,15-EE-8(Z)-E 
during the fi rst 2 (days 0–2) or 4 (days 0–4) days markedly 
attenuated adipocyte differentiation to a similar extent as 
treatment throughout the entire differentiation period 
(days 0–8) ( Fig. 6A, B ). However, initiation of treatment 
of on day 2, day 4, or day 6 elicited dramatically less to no 
effect on adipocyte differentiation. Furthermore, treat-
ment with 14,15-EE-8(Z)-E during days 0–2, 0–4, and 0–8 
dramatically decreased the induction of PPAR  , C/EBP  , 
and SREBP1c mRNA levels at day 2 (the early phase), day 
4 (the intermediate phase), and day 8 (the late phase) com-
pared with vehicle control-treated cells ( Fig. 6D ). Consis-
tent with the lipid accumulation data, however, initiation 
of treatment with 14,15-EE-8(Z)-E beyond the early phase 
(on day 2, day 4, or day 6) had dramatically less to no effect 
( Fig. 6C ). These fi ndings demonstrate that EET analogs sig-
nifi cantly attenuate adipocyte maturation via inhibition of 
the early phase of adipogenesis. 
 Promoting the effects of EETs elicits protective effects in 
diet-induced obesity in vivo 
 Administration of EET-A, an EET analog conducive to 
administration in the drinking water ( 14 ), signifi cantly 
attenuated HFD-evoked body weight gain ( Fig. 7A ) and 
 Modulation of the CYP epoxygenase pathway alters 
adipocyte differentiation in vitro 
 In order to elucidate the functional role of the CYP 
epoxygenase pathway in the regulation of adipogenesis, 
we fi rst differentiated 3T3-L1 preadipocytes to mature adipo-
cytes in the presence of the CYP epoxygenase inhibitor, MS-
PPOH. Administration of MS-PPOH dose-dependently 
increased lipid accumulation in mature adipoctyes 
( Fig. 4A, B ). Due to the instability of exogenously admin-
istered EETs, follow-up experiments were completed using 
the stable EET analogs, NUDSA and 14,15-EE-8(Z)-E. 
Administration of NUDSA ( Fig. 4C, D ) and 14,15-EE-8(Z)-
E ( Fig. 4E, F ) each attenuated the differentiation of 3T3-
L1 preadipocytes into mature adipocytes. Furthermore, 
14,15-EE-8(Z)-E dose-dependently downregulated the in-
duction of the adipocyte differentiation associated transcrip-
tion factors PPAR  , C/EBP  , and SREBP1c ( Fig. 5A–C ), 
and the adipocyte differentiation-associated genes LPL, 
ACC1, FAS, and Fabp4 ( Fig. 5D–G ). Altogether, these fi nd-
ings implicate the CYP epoxygenase pathway as a key func-
tional regulator of adipogenesis. 
 Administration of an EET analog suppresses adipocyte 
differentiation in the early phase 
 Due to the marked reduction of EET levels during the 
early phases of adipocyte differentiation, we sought to de-
 Fig.  1. EET levels are reduced in 3T3-L1 mature adipocytes compared with preadipocytes. A: 3T3-L1 preadipocytes (P) and mature adi-
pocytes (M) (differentiated for 8 days) were fi xed and stained by Oil Red O (scale bar = 40   m). B:  Fabp4 mRNA levels were quantifi ed by 
qRT-PCR (n = 3 per group) to confi rm adipocyte differentiation. C: The culture medium was collected every 2 days during the differentia-
tion period, and a total of 33 distinct eicosanoid metabolites were quantifi ed by HPLC-MS/MS. A PCA demonstrates a clear separation of 
the global eicosanoid profi les across preadipocytes and differentiated adipocytes. Preadipocytes are shown as green dots (days 0–2), cyan 
dots (days 2–4), yellow dots (days 4–6), and black dots (days 6–8); differentiated adipocytes are shown as red dots (days 0–2), blue dots 
(days 2–4), gray dots (days 4–6), and purple dots (days 6–8). D: Specifi c evaluation of the CYP epoxygenase-derived arachidonic acid me-
tabolite pathway demonstrated that the sum EET, sum DHET, and sum EET+DHET concentrations normalized by cell density (days 6–8) 
were signifi cantly reduced in 3T3-L1 mature adipocytes compared with preadipocytes (n = 4 per group). E–G: The reduction of the sum 
EET (E), sum DHET (F), and sum EET+DHET (G) concentrations were apparent after 2 days and sustained throughout the entire dif-
ferentiation period (n = 4 per group). * P < 0.05 versus preadipocytes. 
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of experiments, mice with targeted disruption of  Ephx2 
and significantly higher endogenous EETs in eWAT 
(14,15-EET:DHET: 4.27 ± 0.54 vs. 0.13 ± 0.06, respectively, 
 P < 0.05 vs. WT) underwent HFD feeding for 4–8 weeks. 
Although a signifi cant decrease in body weight gain was 
not observed ( Fig. 9A, C ),  Ephx2   /   mice exhibited a sig-
nifi cantly attenuated induction of PPAR  and LPL mRNA 
levels in eWAT ( Fig. 9B, D ) and systemic glucose intoler-
ance ( Fig. 9E–H ) compared with WT controls at both 
4 and 8 weeks. Taken together, these results indicate that 
therapeutic restoration of EETs elicits metabolic protec-
tive effects in diet-induced obesity in vivo. 
 DISCUSSION 
 Adipogenesis plays a key role in the initiation and pro-
gression of obesity and obesity-associated metabolic dis-
eases. Although CYP epoxygenase-derived EETs possess 
potent protective effects in the cardiovascular system 
( 7, 8 ), the functional role of EETs in the regulation of adi-
pogenesis and the pathogenesis of obesity remains poorly 
understood. In the present investigation, we demonstrated 
that:  a ) adipogenesis and obesity-associated adipose ex-
pansion signifi cantly dysregulate the CYP epoxygenase 
pathway and evoke a marked suppression of EET levels in 
adipose tissue; and  b ) potentiating the effects of EETs elic-
its potent anti-adipogenic and anti-obesity effects both in 
vitro and in vivo. Collectively, these fi ndings suggest that 
suppression of EET bioavailability in adipose tissue is a key 
pathological consequence in the early stages of obesity, 
adipose tissue expansion ( Fig. 7B–D ) compared with 
vehicle-treated controls. These effects were not accompa-
nied with a reduction in food consumption ( Fig. 7E ). As-
sessment of metabolic capacity illustrated that EET-A 
administration attenuated the HFD-evoked suppression of 
energy expenditure compared with vehicle-treated con-
trols ( Fig. 7F–I ), although the observed increase in O 2 
consumption ( Fig. 7F ,  P = 0.149) and metabolic rate ( Fig. 
7I ,  P = 0.089) was not statistically signifi cant. EET-A treat-
ment also signifi cantly increased expression of UCP1 in 
BAT ( Fig. 7J ). 
 Furthermore, EET-A treatment signifi cantly attenuated 
the induction of systemic glucose intolerance ( Fig. 7K, L ). 
Although EET-A did not signifi cantly reduce fasting ( Fig. 
7K ; time 0) or fed ( Fig. 7M ) blood glucose concentrations, 
high-fat feeding did not signifi cantly increase fasting ( P = 
0.107) or fed ( P = 0.350) glucose levels compared with the 
control diet, illustrating the prediabetic state (i.e., obesity 
and glucose intolerance without overt diabetes) at 4 weeks. 
 Administration of NUDSA, an EET analog conducive to 
repeated dosing in vivo ( 13 ), also signifi cantly attenuated 
HFD-evoked weight gain ( Fig. 8A ) compared with vehicle-
treated controls without affecting average food con-
sumption (16.1 ± 0.8 g/week/mouse vs. 17.5 ± 1.2 g/week/
mouse, respectively,  P = 0.468). Furthermore, and con-
sistent with the effects elicited by EET-A, the induction of 
eWAT mass ( Fig. 8B ), adipocyte hypertrophy ( Fig. 8C, D ), 
and expression of the adipogenic markers PPAR  and 
LPL in eWAT ( Fig. 8E ) were signifi cantly attenuated 
and expression of UCP1 in BAT was significantly aug-
mented ( Fig. 8F ) by NUDSA treatment. In a parallel series 
 Fig.  2. Characterization of CYP epoxygenase and sEH expression and activity in 3T3-L1 preadipocytes and mature adipocytes. 3T3-L1 
preadipocytes (P) and mature adipocytes (M) (differentiated for 8 days) were harvested. A: The relative abundance of CYP epoxygenase 
and epoxide hydrolase mRNA levels were quantifi ed in 3T3-L1 preadipocytes (N.D., not detected) and normalized to GAPDH (n = 3 per 
group). B–D: Representative immunoblot and densitometry analysis demonstrate lower Cyp2j9 (B) and Cyp2c55 (C) and higher sEH (D) 
protein expression in mature adipocytes compared with preadipocytes (n = 3 per group). Sum EET+DHET (E) and sum EET (F) concen-
trations following incubation with 10   M arachidonic acid for 30 min (biomarker of CYP epoxygenase metabolic activity). G: The 
14,15-EET:DHET ratio following incubation with 25 ng 14,15-EET for 10 min [biomarker of sEH activity (lower ratio indicative of higher 
activity)] were each signifi cantly reduced in mature adipocytes (n = 4 per group). * P < 0.05 versus preadipocytes. 
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and increased sEH-mediated hydrolysis. Importantly, con-
sistent with our experiments in cultured 3T3-L1 adipo-
cytes and a recent report in rats ( 9 ), induction of obesity 
and adipose tissue expansion in mice with high fat feeding 
signifi cantly suppressed EET concentrations in eWAT. 
Moreover, we observed a marked suppression of each EET 
and DHET regioisomer in eWAT, which were inversely 
correlated with body weight gain, eWAT weight, and adi-
pogenesis-related transcription factor expression. We also 
observed a signifi cant inverse correlation between pro-
infl ammatory cytokine expression and EET levels in eWAT. 
Our previous studies have demonstrated that activation 
of the innate immune infl ammatory response suppresses 
hepatic EET biosynthesis ( 22 ). Given the integral contri-
bution of infl ammation in visceral adipose tissue to the 
pathogenesis of obesity ( 4 ), activation of obesity-associated 
infl ammatory responses may also drive the suppression of 
EET bioavailability in adipose tissue. However, future stud-
ies are needed to elucidate these effects and the underly-
ing mechanisms. It is important to note that we did not 
quantify EET concentrations in multiple adipose tissue 
depots, which is a limitation. Comprehensive evaluation of 
the relative impact of obesity on EET levels across distinct 
adipose tissue depots, as well as across species, remains an 
important future direction for this line of investigation. 
 In addition to the observed suppression of EET bioavail-
ability during adipocyte differentiation, further inhibition 
of EET biosynthesis via administration of a CYP epoxygen-
ase inhibitor signifi cantly accelerated adipogenesis. Col-
lectively, these data suggest that CYP-derived EETs play an 
and strategies that promote the protective effects of EETs 
in adipose tissue offers enormous therapeutic potential 
for obesity-associated metabolic diseases. 
 We recently reported that obesity was associated with 
signifi cantly lower circulating EET levels in humans with 
established cardiovascular disease ( 26 ). Although prior 
studies have demonstrated that experimental induction 
of obesity reduces EETs in liver, kidney, and mesenteric 
arteries ( 21, 31 ), as well as alters cyclooxygenase-mediated 
prostaglandin biosynthesis and lipoxygenase-mediated 
leukotriene biosynthesis in adipose tissue ( 32, 33 ), the im-
pact of obesity on EET bioavailability in adipose tissue has 
not been rigorously investigated . Consequently, we em-
ployed a metabolomic approach to characterize the 
global eicosanoid profi le during adipocyte differentia-
tion in 3T3-L1 cells. Adipocyte maturation signifi cantly al-
tered the global eicosanoid profi le; however, the CYP 
epoxygenase-derived EETs and DHETs were markedly 
suppressed and the most signifi cantly changed metabo-
lites compared with parallel pathways. Moreover, Cyp2j9 
and Cyp2c55 expression were suppressed and sEH expres-
sion was induced in mature adipocytes, consistent with 
prior reports in mesenchymal stem cells and 3T3-L1-de-
rived adipocytes ( 34, 35 ). Our studies also demonstrate a 
signifi cant functional suppression of CYP epoxygenase 
(decreased EET+DHET formation) and induction of ep-
oxide hydrolase (increased 14,15-EET hydrolysis) meta-
bolic activity in mature adipocytes, suggesting that the 
adipogenesis-evoked suppression of EET levels is second-
ary to both suppressed Cyp2c/2j-mediated biosynthesis 
 Fig.  3. Induction of obesity with HFD feeding signifi cantly suppressed adipose EET and DHET levels in mice. Mice were fed a low-fat 
control diet [Control; D12450B (10% kcal fat)], a high-fat Western diet [HFD-1; D12079B (41% kcal fat)], and a VHFD [HFD-2; D12492 
(60% kcal fat)] for 4 weeks (n = 6 per group) to induce obesity and adipose tissue expansion. A–D: HFD-1 and HFD-2 each increased weight 
gain (A) and eWAT weight (normalized to body weight) (B), and suppressed eWAT EET and DHET concentrations [individual regioiso-
mer (C) and sum total (D); normalized to tissue weight] compared with the control diet. Except for 8,9-EET levels, which were below the 
detection limit in three of six Western and six of six VHFD-fed mice, all EET and DHET regioisomers were detectable in the eWAT of lean 
and obese animals. E–F: eWAT EET concentration exhibited a signifi cant inverse correlation with eWAT weight (E) and TNF  mRNA levels 
in eWAT (quantifi ed by qRT-PCR and normalized to GAPDH) (F). The Spearman’s rank correlation coeffi cient and accompanying  P value 
are provided. * P < 0.05 versus control diet group. 
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promotion of EETs elicits potent anti-adipogenic effects. 
Other EET analogs have been reported to attenuate 
adipogenesis in human mesenchymal stem cell-derived 
adipocytes ( 34, 36, 37 ). Taken together, these studies and 
our experiments demonstrate the potent anti-adipogenic 
integral functional role in the regulation of adipogenesis. 
Furthermore, two distinct EET analogs (14,15-EE-8(Z)-E 
and NUDSA) each dose-dependently inhibited lipid ac-
cumulation and adipocyte differentiation-associated gene 
expression, clearly demonstrating that pharmacologic 
 Fig.  4. Modulation of the CYP epoxygenase pathway alters adipocyte differentiation of 3T3-L1 cells. 3T3-L1 
cells were induced to differentiate while concurrently being treated with MS-PPOH (1, 5, 10, and 20   M), 
NUDSA (1, 5, and 10   M), 14,15-EE-8(Z)-E (0.1, 0.5, and 1.0   M), or vehicle for 8 days. A, C, E: Representative 
images of Oil Red O-stained adipocytes treated with MS-PPOH (A), NUDSA (B), and 14,15-EE-8(Z)-E (C) are 
provided (scale bar = 40   m). B, D, F: Cellular lipid content was quantifi ed by spectrophotometry after elution 
with isopropanol, and then normalized to the vehicle control group (n = 3–6 per group). All data are expressed 
relative to the vehicle control group. * P < 0.05 versus vehicle control. Pre, preadipocyte; Ctrl, control . 
 Fig.  5. Administration of the EET analog 14,15-EE-8(Z)-E reduces adipogenic gene expression in 3T3-L1 cells. 3T3-L1 cells were induced 
to differentiate while concurrently being treated with 14,15-EE-8(Z)-E (0.1, 0.5, and 1.0   M) or vehicle for 8 days. PPAR  (A), C/EBP  (B), 
SREBP1c (C), LPL (D), ACC1 (E), FAS (F), and Fabp4 (G) mRNA levels were quantifi ed by qRT-PCR and normalized to GAPDH (n = 3 
per group). Similar results were observed after the data were normalized to   -actin (data not shown). All data are expressed relative to the 
vehicle control group. * P < 0.05 versus vehicle control. Pre, preadipocyte; Ctrl, control. 
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 Promoting the effects of EETs also elicited potent 
metabolic protective effects in vivo. Most notably, EET 
analog administration signifi cantly mitigated HFD-in-
duced weight gain, adipose tissue expansion, and adipo-
cyte differentiation-associated gene expression. Although 
the attenuation of weight gain by EET analog treatment 
was not accompanied by a reduction in food consump-
tion, food absorption was not quantifi ed. Because 
changes in intestinal absorption of calories could con-
tribute, at least in part, to the observed weight gain phe-
notypes, this is a limitation. However, EET analog 
administration attenuated the HFD-evoked suppression 
of whole-body energy expenditure and augmented ex-
pression of the mitochondrial protein carrier UCP1. 
UCP1, which is highly expressed in BAT and dissipates 
chemical energy in the mitochondria in the form of heat 
via fatty acid oxidation, is a critical regulator of energy 
expenditure in adipose tissue and dysregulation of this 
process is a key driver of the pathogenesis of obesity ( 44, 
45 ). Taken together, these data suggest that promoting 
the effects of EETs attenuates adipose expansion and 
weight gain by enhancing metabolic effi ciency in adipose 
tissue. The anti-obesity effects in HFD-fed mice and the 
anti-adipogenic effects in differentiated 3T3-L1 cells are 
challenging to reconcile because adipocyte hypertrophy, 
and not hyperplasia, has been traditionally recognized as 
the primary driver of adipose tissue expansion in obesity 
( 5 ). It is important to note, however, recent studies have 
demonstrated that de novo adipogenesis also is an im-
portant contributor to HFD-induced obesity ( 46 ), high-
lighting the important but complex contribution of 
effects of multiple EET analogs in multiple cell systems. 
Furthermore, our experiments demonstrate for the fi rst 
time that EET analog treatment elicits its anti-adipogenic 
effects through targeting the biochemical and cellular 
events in the early phase of adipogenesis, which are crucial 
for adipocyte differentiation ( 38 ). This was refl ected by 
the marked and early suppression of PPAR  , C/EBP  , and 
SREBP1c mRNA levels that were sustained throughout the 
entire differentiation period. Moreover, initiation of EET 
analog treatment during the late phase of differentiation 
failed to inhibit either the induction of adipogenic tran-
scription factor expression or lipid accumulation. 
 It is well-established that activation of PPAR  , C/EBP  , 
and SREBP1c are central mediators of adipogenesis through 
their regulation of lipid biosynthesis and metabolism 
( 2, 3 ) Several mechanisms are known to regulate this tran-
scriptional factor network. During the early differentia-
tion of preadipocytes, inhibition of ERK and activation of 
the AMP-activated protein kinase (AMPK) and cAMP/pro-
tein kinase A (PKA) signaling pathways inhibit PPAR  , 
C/EBP  , and SREBP1c activation and adipocyte differen-
tiation ( 39–41 ). Previous studies have demonstrated that 
promoting the effects of EETs attenuates ERK1/2 dephos-
phorylation in endothelial cells, activates AMPK activity in 
liver, and activates the cAMP/PKA pathway in the vascular 
system ( 12, 42, 43 ), suggesting that a complex interaction 
between CYP-derived EETs and multiple signaling path-
ways also likely exist in the early phase of adipogenesis. 
Future studies are needed to delineate the key signaling 
pathways that underlie the inhibitory effects of EETs on 
adipocyte differentiation. 
 Fig.  6. The early stages of adipogenesis are critical to the anti-adipogenic effects of the EET analog, 14,15-EE-8(Z)-E. 3T3-L1 cells were 
differentiated to mature adipocytes for 8 days. A: 14,15-EE-8(Z)-E (1   M) was administered during the time period indicated. Representa-
tive images of Oil Red O-stained adipocytes on day 8 are provided for each treatment group (scale bar = 40   m). B: Cellular lipid content 
was quantifi ed by spectrophotometry after elution with isopropanol, and then normalized to the vehicle control group (n = 3 per group). 
C: PPAR  mRNA levels were quantifi ed by qRT-PCR in 3T3-L1 cells on day 8. 3T3-L1 cells were differentiated in the presence of 14,15-EE-
8(Z)-E (1   M) or vehicle (0.1% DMSO) control for 0–2, 0–4, or 0–8 days. D: PPAR  , C/EBP  , and SREBP1c mRNA levels were quantifi ed 
by qRT-PCR on day 2, 4, or 8, respectively (n = 3 per group). The data were normalized to GAPDH and expressed relative to the vehicle 
control group. * P < 0.05 versus vehicle control. Pre, preadipocyte; Ctrl, control. 
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differences, including the potential for compensatory 
changes secondary to gene disruption, remain unclear 
and warrant further investigation. Induction of adipocyte 
differentiation-associated transcription factor and lipo-
genic gene expression following high fat feeding, how-
ever, was significantly attenuated in  Ephx2   /   mice. 
Multiple studies have demonstrated that inhibition of 
adipogenic transcriptional factor activation ameliorates 
HFD-induced glucose intolerance ( 47, 48 ). Moreover, 
early-onset glucose intolerance during high-fat feeding 
is primarily driven by lipid overload ( 49 ), as opposed to 
other mechanisms including hepatic infl ammation, pan-
creatic dysfunction, and systemic insulin resistance, that 
are more pronounced in the later stages of obesity. Thus, 
our experiments suggest that promoting the effects of 
EETs in adipose tissue contribute to improved glucose tol-
erance during the early stages of obesity, at least in part, 
through attenuating the activation of pro-adipogenic gene 
expression; however, future studies remain necessary to 
adipogenesis to obesity. Consequently, future studies are 
needed to delineate the relative contribution of adipo-
cyte hyperplasia and hypertrophy, and the underlying 
molecular mechanisms to the anti-obesity effects of EET 
analogs in vivo. 
 The development of glucose intolerance is a critical 
pathological consequence of obesity, which drives the de-
velopment of type 2 diabetes ( 4 ). Administration of the 
EET analog, EET-A, signifi cantly abrogated the HFD-
evoked induction of glucose intolerance in vivo. Similarly, 
mice with targeted disruption of  Ephx2 and restored en-
dogenous EET levels exhibited an attenuated induction of 
glucose intolerance following 4 and 8 weeks of high-fat 
feeding. In contrast to EET analog treatment, weight gain 
was not attenuated in  Ephx2   /   mice. These data are con-
sistent with a prior report illustrating improved glucose 
tolerance in  Ephx2   /   mice without changes in weight 
gain, compared with WT controls, after 20 weeks of 
HFD feeding ( 11 ). The mechanisms underlying these 
 Fig.  7. The EET analog, EET-A, elicits anti-obesity effects and attenuates glucose intolerance in mice fed a HFD. Mice were fed a HFD 
(D12492) or control diet for 4 weeks (n = 4–8 per group). HFD-fed mice were treated with EET-A (100 mg/l in the drinking water) or 
vehicle control for 4 weeks. A–D: Compared with vehicle, EET-A treatment attenuated the HFD-induced increase in total body weight 
gain from baseline (A), fat mass gain (EchoMRI) from baseline (B), fat mass (EchoMRI) expressed as a percentage of total body weight 
(C), and eWAT mass at necropsy normalized by body weight (D). E: Cumulative food consumption over 24 h. F–I: Energy expenditure 
phenotypes, including VO 2 (F), VCO 2 (G), the RER (H), and the metabolic rate (I), were assessed at week 3. Energy expenditure phe-
notypes were averaged over 24 h and normalized to body weight. J: BAT mRNA levels of UCP1 were quantifi ed by qRT-PCR, normalized 
to GAPDH, and expressed relative to the control diet group. K: At 4 weeks, blood glucose concentrations were quantifi ed at baseline 
(fasting) and over 120 min following an intraperitoneal glucose tolerance test. The repeated measures ANOVA  P value is provided. L: 
The corresponding AUC at 4 weeks was calculated. M: Blood glucose concentrations (fed) were quantifi ed at necropsy. * P < 0.05 versus 
HFD-vehicle. 
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and suggest that suppression of EET bioavailability in adi-
pose tissue is a key pathological consequence of obesity. 
Therapeutic strategies that promote the protective effects 
of EETs in adipose tissue offer enormous potential to miti-
gate obesity-associated metabolic disease and its down-
stream pathological consequences.  
delineate these effects and elucidate the underlying mech-
anisms, and to evaluate the metabolic protective effects of 
EET analog treatment during the later stages of obesity. 
 In summary, our studies demonstrate that CYP epoxy-
genase-derived EETs play an integral functional role in the 
regulation of adipogenesis and the pathogenesis of obesity, 
 Fig.  8. The EET analog NUDSA elicits anti-obesity effects in mice fed a HFD. Mice were fed a HFD (D12492) or control diet for 2 weeks (n = 6 
per group). HFD-fed mice were treated with either NUDSA (15 mg·kg   1 ·day   1 ) or vehicle control via intraperitoneal injection once daily for 2 
weeks. A, B: Compared with vehicle, NUDSA treatment attenuated the HFD-induced increase in total body weight gain from baseline (A) and 
eWAT mass at necropsy normalized by body weight (B). C: Representative images of H&E-stained eWAT sections (magnifi cation 20×) are pro-
vided. D: Average adipocyte size per 10× fi eld was quantifi ed using ImageJ. eWAT mRNA levels of PPAR  and LPL (E) and BAT mRNA levels of 
UCP1 (F) were quantifi ed by qRT-PCR, normalized to GAPDH, and expressed relative to the control diet group. * P < 0.05 versus HFD-vehicle. 
 Fig.  9.  Ephx2   /   mice exhibit attenuated eWAT activation and glucose intolerance following HFD feeding.  Ephx2   /   and WT mice were 
fed a HFD (D12079B) or control diet (WT-Control, n = 6; WT-HFD, n = 14; KO-HFD, n = 11) for 4 or 8 weeks. A, C: Total body weight gain 
from baseline was quantifi ed at 4 weeks (A) and 8 weeks (C). B, D: PPAR  and LPL mRNA levels in eWAT at 4 weeks (n = 3 per group) (B) 
and 8 weeks (D) (WT-Control, n = 6; WT-HFD, n = 10; KO-HFD, n = 8) were quantifi ed by qRT-PCR, normalized to GAPDH, and expressed 
relative to the control diet group. E–H: Blood glucose concentrations were quantifi ed at baseline (fasting) and over 120 min following an 
intraperitoneal glucose tolerance test at 4 weeks (WT-Control, n = 6; WT-HFD, n = 14; KO-HFD, n = 11) (E) and 8 weeks (WT-Control, n = 
6; WT-HFD, n = 10; KO-HFD, n = 8) (G). The repeated measures ANOVA  P value is provided. The corresponding AUC at 4 weeks (F) and 
8 weeks (H) was calculated. No signifi cant differences in fasting [week 4 (E),  P = 0.071); week 8 (G),  P = 0.155] or fed (week 8,  P = 0.516) 
glucose levels between  Ephx2   /   and WT mice were observed. * P < 0.05 versus WT-HFD. 
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